Oncotarget
The cover for issue 10 of Oncotarget features Figure 3, "Overall survival (OS) for high (red) versus low (black) risk groups in the (A) OSU, (B) TCGA, and (C) SNU resected cohorts," by Wolfe, et al.
MicroRNA (miR) dysregulation during Helicobacter pylori-induced gastric inflammation and cancer development: critical importance of miR-155 |
https://doi.org/10.18632/oncotarget.27520 Christian Prinz, and David Weber |
894-904 |
Abstract | PDF | Full Text | How to cite | Press Release | Order a Reprint |
DNA methylation of MMPs and TIMPs in atherothrombosis process in carotid plaques and blood tissues |
https://doi.org/10.18632/oncotarget.27469 Cristina Gallego-Fabrega, Natalia Cullell, Carolina Soriano-Tárraga, Caty Carrera, Nuria P. Torres-Aguila, Elena Muiño, Jara Cárcel-Márquez, Manuel Castro de Moura, Alba Fernández-Sanlés, Manel Esteller, Roberto Elosua, Jordi Jiménez-Conde, Jaume Roquer, Joan Montaner, Jerzy Krupinski, and Israel Fernandez-Cadenas |
905-912 |
Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release | Order a Reprint |
A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection |
https://doi.org/10.18632/oncotarget.27496 Adam R. Wolfe, Patrick Wald, Amy Webb, Nikhil Sebastian, Steve Walston, Ryan Robb, Wei Chen, Marall Vedaie, Mary Dillhoff, Wendy L. Frankel, Wooil Kwon, Jin-Young Jang, and Terence M. Williams |
913-923 |
Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release | Order a Reprint |
Prognostic and predictive factors in pancreatic cancer |
https://doi.org/10.18632/oncotarget.27518 Emanuela Dell’Aquila, Claudia Angela Maria Fulgenzi, Alessandro Minelli, Fabrizio Citarella, Marco Stellato, Francesco Pantano, Marco Russano, Maria Concetta Cursano, Andrea Napolitano, Tea Zeppola, Bruno Vincenzi, Giuseppe Tonini, and Daniele Santini |
924-941 |
Abstract | PDF | Full Text | How to cite | Press Release | Order a Reprint |
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* |
https://doi.org/10.18632/oncotarget.27512 David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan, Edmund A. Rossi, and Robert M. Sharkey |
942-942 |
Correction | PDF | How to cite |
Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC